Medicare to weigh national coverage for Aduhelm, other Alzheimer’s treatments … Neurologists issue ethical guidance for dementia diagnosis and care … Helping seniors hear better may slow decline...
Lilly to seek FDA approval for new drug for Alzheimer’s disease
Jun 25, 2021
Donanemab already has received a ‘breakthrough therapy’ designation from the FDA.
Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.
New Rx instructions tighten use of controversial Alzheimer’s disease drug
Jul 08, 2021
Major changes to prescribing instructions are rare, especially so soon after approval; it change could curb the drug’s use.
More news for Wednesday, May 4
By
Kimberly Bonvissuto
May 04, 2022
Occupancy trends up after omicron slump: Omega … AHCA / NCAL launches Diversity Executive Leadership Program … How to support older adults related to gun ownership decisions, suicide prevention …...
Home Care briefs for Wednesday, June 16
By
Diane Eastabrook
Jun 16, 2021
Acclivity Health and Vytalize Health partner on plan to improve care for palliative care patients … Alzheimer’s Association endorses FDA approval of Aduhelm, criticizes drug price … PACE growth is...
More news for Thursday, Feb. 1
By
Kimberly Bonvissuto
Feb 01, 2024
Federal standards, employer preparedness plans need improving to protect frontline workers: study … Joint federal agency letter urges utility data access for affordable housing providers … LeadingAge...
More news for Friday, April 8
By
Kimberly Bonvissuto
Apr 08, 2022
CBRE Seniors Housing & Care Investor Survey identifies industry trends … Senior housing staffing shortages move from severe to moderate: NIC … CMS finalizes Medicare coverage policy for Alzheimer’s...
Few older adults knowledgeable about aducanumab for Alzheimer’s disease
Feb 25, 2022
Less than one-quarter of older adults report they would want to take aducanumab (Aduhelm).
Ethical considerations explored for aducanumab in Alzheimer’s disease
Nov 19, 2021
Grounds are insufficient to offer aducanumab (Aduhelm) for moderate, advanced Alzheimer’s dementia or for individuals without biomarker evidence of brain ß-amyloid, according to a position statement.